Doctolib

Company research

Public company, workplace, funding, and market signals

Updated Aug 5, 2026

Overview

Doctolib is a privately held European digital-health company founded in 2013. It provides a patient-facing health companion and a software operating system for healthcare professionals, combining appointment discovery and booking, teleconsultation, communications, practice administration, clinical/financial workflows and AI-enabled assistants. In its 2025 corporate presentation, Doctolib reported 3,000 employees, 420,000 healthcare professionals and 90 million patients across France, Germany, Italy and the Netherlands.

Primary product

A subscription healthcare platform: patients search for and book care, while healthcare professionals use Doctolib’s operating system for scheduling, digital secretariat, telehealth, patient communications, clinical/practice management, billing and increasingly AI-assisted documentation and workflow.

Founded

2013

Headquarters

Levallois-Perret, Île-de-France, France

Team size

2,800–3,600; official 2025 presentation says approximately 3,000

Work style

Flexible

Industry

Healthcare technology / digital health

Sub-industry

Healthcare IT, medical practice-management SaaS, telemedicine and healthcare marketplace

Offices

Levallois-Perret, France (HQ)

Paris, France

Nantes, France

Niort, France

Berlin, Germany

Hamburg, Germany

Milan, Italy

Rome, Italy

Amsterdam, Netherlands

Business model

B2B SaaS subscriptions paid by healthcare professionals and organizations

Patient-facing marketplace subsidized by professional subscriptions

Enterprise and institutional healthcare software

Teleconsultation and clinical workflow software

Funding

Stage

Late-stage venture-backed / private, generating revenue (Series G); no public IPO

Total raised

$866M

Latest round

Series G (additional reported tranche) · Aug 2022

Latest amount

$51M

Series G / strategic investment

Aug 2022 · SanteVet

$51M

Debt

Mar 2022

Series G / late-stage round

Mar 2022 · Eurazeo; Bpifrance; General Atlantic

$549M

Series E

Mar 2019 · General Atlantic

$170M

Series D

Nov 2017 · Eurazeo; Bpifrance

$42M

Series C

Jan 2017 · Bpifrance

$28M

Series B

Oct 2015 · Accel

$20M

Angel

Nov 2014 · Bertrand Jelensperger; Pierre Kosciusko-Morizet

$5M

Seed

Feb 2014

$1.2M

People & investors

Leadership

Stanislas Niox-Chateau

Co-founder, Chairman and CEO

Alex Kaluzny

Chief Technology Officer

Pierre Vergnes

Group Chief Financial Officer

Matthieu Birach

Chief People Officer

Steve Abou Rjeily

Co-founder and Director of Sales

Investors

Accel

Antoine Freysz

Bertrand Jelensperger

Kernel Capital / Kernel Investissements

Maxime Forgeot

Nicolas Brusson

Olivier Occelli

Pierre Kosciusko-Morizet

Pierre Krings

SanteVet

Work & culture

Mission-led, patient- and healthcare-professional-centric culture. The company describes itself as a medical company, emphasizes humility, perseverance, teamwork, a bold north star and production-grade technology/AI designed to support rather than replace clinicians. Careers materials also emphasize inclusion, women in tech and product, mentoring and continuous learning.

Work style

Flexible

Compensation

Public job postings show benefits and an employee value-sharing plan, but no reliable company-wide salary bands were found. Some international roles advertise relocation support; visa sponsorship is not clearly stated.

Benefits

Company-paid health insurance for employee and children

25 days paid leave plus up to 14 RTT days (country/role dependent)

Mental-health and coaching support through Moka.care

Parent Care Program with an additional month of leave

Flexible/hybrid workplace policy

Up to 10 work-from-EU/UK days annually under flexibility policy

Lunch vouchers

Public-transport reimbursement

Sports/creative-class subsidy

Relocation support

Doctolib Academy and continuous training

Employee value-sharing plan called DoctoGrowth

Product & market

Pricing

Patients generally use the booking service free of charge; healthcare professionals pay recurring SaaS subscriptions for booking/practice-management, EHR, telemedicine and related modules. Public historical research cited approximately €99–€139/month for core professional booking, with additional annual fees for EHR, telemedicine and devices; current pricing varies by country and product.

Differentiators

—Large integrated patient-and-provider network across major European markets
—Full operating system spanning booking, communications, telehealth, clinical and financial workflows
—High scale: tens of millions of patients and hundreds of thousands of professionals
—Strong healthcare-specific product and regulatory focus
—AI strategy centered on consultation documentation, phone assistance, coding and health navigation
—No patient appointment take-rate; monetization primarily comes from professional subscriptions

Technology

Ruby

Python

Kotlin

React

Kubernetes

Prometheus

OpenTelemetry

Loki

Elasticsearch

Logstash

Vector

ArgoCD

Datadog

Amazon Web Services

Azure AI / large-language-model tooling

Customers

Healthcare professionals and practices

Hospitals and healthcare organizations

Patients and caregivers

Approximately 420,000 healthcare professionals, according to Doctolib’s 2025 presentation

Competitors

DocPlanner / Doctoralia

MioDottore

Doctena

Qare

Keldoc

EMIS

TPP / SystmOne

Scale & contact

Estimated revenue

Approximately $330M–$430M annually (third-party estimates: $331.7M 2023 revenue and $402.6M 2024 revenue; Dealroom reports $100M–$500M).

Estimated monthly visits

33M

Signals & risks

Other

Nov 2025

The French Competition Authority reportedly fined Doctolib €4.66 million for abuse of a dominant position involving exclusivity clauses and the MonDocteur transaction; this is a competition/regulatory risk signal.

Source

Acquisition

May 2026

Doctolib acquired Medicus Health, a London-based primary-care software company, to enter the UK/NHS market; reported expansion plans include a London R&D centre and substantial investment.

Source

Other

Apr 2026

A reported €300 million secondary share sale valued Doctolib at approximately €3.6 billion, below its approximately €5.8 billion 2022 valuation, indicating a material valuation reset even though it was not a primary financing round.

Source

Other

Aug 2026

Doctolib’s clinical-AI research program triggered public debate about default participation, health-data reuse, European hosting and AWS involvement. Doctolib says data is de-identified, encrypted, retained for limited periods and subject to opt-out.

Source